Literature DB >> 31604755

Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.

Sheryl Spithoff1, Christopher Meaney2, Karen Urbanoski3, Katy Harrington4, Bill Que5, Meldon Kahan6, Pamela Leece7, Vivian Shehadeh8, Frank Sullivan9.   

Abstract

OBJECTIVE: To determine access to opioid agonist therapy (OAT) for those entering residential treatment for opioid use disorder; to report on treatment outcomes for those taking OAT and those not taking OAT; and to determine the association between OAT use and residential treatment completion.
DESIGN: Retrospective cohort study.
SETTING: Ontario. PARTICIPANTS: Patients with opioid use disorder admitted to publicly funded residential treatment programs in the province of Ontario between January 1, 2013, and December 31, 2016. MAIN OUTCOME MEASURES: Access to OAT during residential treatment using descriptive statistics. Treatment outcomes (ie, completed the program, voluntarily left early, involuntary discharged, and other) for the entire cohort and for the OAT and non-OAT groups using descriptive statistics. Association between OAT use at admission and treatment completion (a binary outcome) using bivariate and multivariate models.
RESULTS: Among an identified cohort of 1910 patients with opioid use disorder, 52.8% entered programs that permitted access to OAT. Overall, 56.8% of patients completed treatment, 23.3% voluntarily left early (eg, were no-shows, dropped out), 17.0% were involuntarily discharged, and 2.9% were discharged early for other reasons. Those taking OAT were as likely to complete treatment as those not taking OAT (53.9% vs 57.5%, respectively; adjusted odds ratio of 1.07, 95% CI 0.77 to 1.38).
CONCLUSION: This study demonstrates 2 large gaps in care for patients with opioid use disorder. First, these patients have poor access to OAT-the first-line treatment of opioid use disorder-while in publicly funded residential treatment programs; and second, many are involuntarily discharged from treatment. Additionally, this study indicates that patients taking OAT have similar likelihood of completing residential treatment as those not taking OAT do. Limitations of this study are that it is based on observational data for patients who self-selected before admission to use OAT or not, and it is likely not all confounders were accounted for. Copyright© the College of Family Physicians of Canada.

Entities:  

Year:  2019        PMID: 31604755      PMCID: PMC6788647     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  35 in total

1.  Does retention matter? Treatment duration and improvement in drug use.

Authors:  Zhiwei Zhang; Peter D Friedmann; Dean R Gerstein
Journal:  Addiction       Date:  2003-05       Impact factor: 6.526

2.  Correlations between population levels of prescription opioid use and prescription-opioid-related substance use treatment admissions in the USA and Canada since 2001.

Authors:  B Fischer; N Nakamura; K Urbanoski; B Rush; J Rehm
Journal:  Public Health       Date:  2012-07-05       Impact factor: 2.427

3.  Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011.

Authors:  Benedikt Fischer; Wayne Jones; Karen Urbanoski; Roger Skinner; Jürgen Rehm
Journal:  Drug Alcohol Rev       Date:  2013-11-21

4.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

5.  Residential and outpatient treatment completion for substance use disorders in the U.S.: Moderation analysis by demographics and drug of choice.

Authors:  Gerald J Stahler; Jeremy Mennis; Joseph P DuCette
Journal:  Addict Behav       Date:  2016-02-17       Impact factor: 3.913

6.  Premature discharge from methadone treatment: patient perspectives.

Authors:  Heather Schacht Reisinger; Robert P Schwartz; Shannon Gwin Mitchell; James A Peterson; Sharon M Kelly; Kevin E O'Grady; Erica A Marrari; Barry S Brown; Michael H Agar
Journal:  J Psychoactive Drugs       Date:  2009-09

7.  Access to Care for Methadone Maintenance Patients in the United States.

Authors:  Jennifer E Hettema; James L Sorensen
Journal:  Int J Ment Health Addict       Date:  2009-07       Impact factor: 3.836

8.  Methadone patients in the therapeutic community: a test of equivalency.

Authors:  James L Sorensen; Siara Andrews; Kevin L Delucchi; Brian Greenberg; Joseph Guydish; Carmen L Masson; Michael Shopshire
Journal:  Drug Alcohol Depend       Date:  2008-11-14       Impact factor: 4.492

9.  Monitoring Utilization of a Large Scale Addiction Treatment System: The Drug and Alcohol Treatment Information System (DATIS).

Authors:  Nooshin Khobzi Rotondi; Brian Rush
Journal:  Subst Abuse       Date:  2012-06-25

10.  Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016.

Authors:  Puja Seth; Lawrence Scholl; Rose A Rudd; Sarah Bacon
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-03-30       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.